Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany's Boehringer Ingelheim is entering into a strategic alliance with Shanghai-based Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) to construct a cGMP biopharmaceuticals facility in China.
Subscribe to our email newsletter
Scheduled to commence operations early in 2016, the new facility will be the first to use mammalian cell culture technology in the production of biopharmaceuticals in China.
Set to carry out technical process development and cGMP manufacturing, the new facility will offer a range of development and clinical services.
Boehringer Shareholders Committee chairman Christian said, "Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources."
The German company is likely to invest more than €35m in the project, which is expected to provide around 65 job opportunities.
ZJ Base Company general manager Lanzhong Wang said with the government support and a number of innovative medicines being developed by a cluster of middle to small-sized innovative companies in Zhangjiang, the company plans to begin the CMO manufacturing framework on a trial basis.
"This will provide an effective platform for middle and small-sized companies to industrialize their innovations," Wang added.